var data={"title":"Imatinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Imatinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6357?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=imatinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Imatinib: Patient drug information&quot;</a> and <a href=\"topic.htm?path=imatinib-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imatinib: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181929\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gleevec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181930\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gleevec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181958\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181934\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for chronic myeloid leukemia (CML) in complete remission is not yet determined. Discontinuing CML treatment is not recommended unless part of a clinical trial (Baccarani 2009). Imatinib is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic phase: 400 mg once daily; may be increased to 600 mg daily, if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6 to 12 months, or loss of previous hematologic or cytogenetic response. An increase to 800 mg daily has been used (Cortes 2010, Hehlmann 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Accelerated phase or blast crisis: 600 mg once daily; may be increased to 800 mg daily (400 mg twice daily), if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6 to 12 months, or loss of previous hematologic or cytogenetic response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ acute lymphoblastic leukemia (ALL) (relapsed or refractory):</b> Oral: 600 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumors (GIST) (adjuvant treatment following complete resection):</b> Oral: 400 mg once daily; recommended treatment duration: 3 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GIST (unresectable and/or metastatic malignant):</b> Oral: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily), if tolerated, for disease progression. <b>Note:</b> Significant improvement (progression-free survival, objective response rate) was demonstrated in patients with KIT exon 9 mutation with 800 mg (versus 400 mg), although overall survival (OS) was not impacted. The higher dose did not demonstrate a difference in time to progression or OS patients with Kit exon 11 mutation or wild-type status (Debiec-Rychter, 2006; Heinrich, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aggressive systemic mastocytosis (ASM) associated with eosinophilia:</b> Oral: Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100 mg to 400 mg/day in the absence of adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ASM without D816V c-Kit mutation or c-Kit mutation status unknown:</b> Oral: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatofibrosarcoma protuberans (DFSP):</b> Oral: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL):</b> Oral: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase:</b> Oral: Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100 mg to 400 mg/day in the absence of adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic/myeloproliferative disease (MDS/MPD) with PDGF receptor gene rearrangements:</b> Oral: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chordoma, progressive, advanced, or metastatic expressing PDGFRB and/or PDGFB (off-label use):</b> Oral: 400 mg twice daily (Stacchiotti 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Desmoid tumors, unresectable and/or progressive (off-label use):</b> Oral: 300 mg twice daily (BSA &ge;1.5 m<sup>2</sup>), 200 mg twice daily (BSA 1 to 1.49 m<sup>2</sup>), 100 mg twice daily (BSA &lt;1 m<sup>2</sup>) (Chugh 2010) <b>or</b> 400 mg once daily; may increase to 400 mg twice daily if progressive disease on 400 mg daily (Penel 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, advanced or metastatic with C-KIT mutation (off-label use):</b> Oral: 400 mg twice daily (Carvajal 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stem cell transplant (SCT, off-label use) for CML (in patients who have not failed imatinib therapy prior to transplant):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylactic use to prevent relapse post SCT:</i> 400 mg daily starting after engraftment for 1 year post transplant (Carpenter 2007) <b>or</b> 300 mg daily starting on day +35 post SCT (increased to 400 mg within 4 weeks) and continued until 12 months post transplant (Olavarria 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relapse post SCT:</i> Initial: 400 mg daily; if inferior response after 3 months, dose may be increased to 600 to 800 mg daily (Hess 2005) <b>or</b> 400 to 600 mg daily (chronic phase) <b>or</b> 600 mg daily (blast or accelerated phase) (DeAngelo 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant strong CYP3A4 inducers:</b> Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181948\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=imatinib-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imatinib: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for CML in complete remission is not yet determined. Imatinib is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (newly diagnosed):</b> Children &ge;1 year and Adolescents: Oral: 340 mg/m<sup>2</sup>/day (in combination with chemotherapy); may be administered as a once daily dose; maximum: 600 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ chronic myeloid leukemia (CML), chronic phase, newly diagnosed:</b> Children &ge;1 year and Adolescents: Oral: 340 mg/m<sup>2</sup>/day (either as a single daily dose or in 2 divided doses); maximum: 600 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment with concomitant strong CYP3A4 inducers:</b> Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181935\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6797530\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 40 to 59 mL/minute: Maximum recommended dose: 600 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 20 to 39 mL/minute: Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;20 mL/minute: Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment (Gibbons 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181936\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: Reduce dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for hepatotoxicity (during therapy):</b> If elevations of bilirubin &gt;3 times ULN or transaminases &gt;5 times ULN occur, withhold treatment until bilirubin &lt;1.5 times ULN and transaminases &lt;2.5 times ULN. Resume treatment at a reduced dose as follows  (<b>Note:</b> The decision to resume treatment should take into consideration the initial severity of hepatotoxicity):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 400 mg daily, reduce dose to 300 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 600 mg daily, reduce dose to 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 800 mg daily, reduce dose to 600 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;1 year and Adolescents: If current dose 340 mg/m<sup>2</sup>/day, reduce dose to 260 mg/m<sup>2</sup>/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181959\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Hematologic toxicity:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic phase CML (initial dose 400 mg daily in adults or 340 mg/m<sup>2</sup>/day in children); ASM, MDS/MPD, and HES/CEL (initial dose 400 mg daily); or GIST (initial dose 400 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L: Withhold until ANC &ge;1.5 x 10<sup>9</sup>/L and platelets &ge;75 x 10<sup>9</sup>/L; resume treatment at original starting dose. For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment at a reduced dose as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;1 year and Adolescents: If initial dose 340 mg/m<sup>2</sup>/day, reduce dose to 260 mg/m<sup>2</sup>/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: If initial dose 400 mg daily, reduce dose to 300 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CML (accelerated phase or blast crisis): Adults (initial dose 600 mg daily): If ANC &lt;0.5 x 10<sup>9</sup>/L and/or platelets &lt;10 x 10<sup>9</sup>/L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg daily. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg daily. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC &ge;1 x 10<sup>9</sup>/L and platelets &ge;20 x 10<sup>9</sup>/L, then resume treatment at 300 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ASM associated with eosinophilia and HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase: Adults (starting dose 100 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L: Withhold until ANC &ge;1.5 x 10<sup>9</sup>/L and platelets &ge;75 x 10<sup>9</sup>/L; resume treatment at previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DFSP: Adults (initial dose 800 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L, withhold until ANC &ge;1.5 x 10<sup>9</sup>/L and platelets &ge;75 x 10<sup>9</sup>/L; resume treatment at reduced dose of 600 mg daily.  For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment with a further dose reduction to 400 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ph+ ALL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics (Schultz 2009): Hematologic toxicity requiring dosage adjustments was not observed in the study. No major toxicities were observed with imatinib at 340 mg/m<sup>2</sup>/day in combination with intensive chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (initial dose 600 mg daily): If ANC &lt;0.5 x 10<sup>9</sup>/L and/or platelets &lt;10 x 10<sup>9</sup>/L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg daily. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg daily. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC &ge;1 x 10<sup>9</sup>/L and platelets &ge;20 x 10<sup>9</sup>/L, then resume treatment at 300 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Nonhematologic toxicity (eg, severe edema):</i></b> Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181906\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gleevec: 100 mg, 400 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181892\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181909\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Should be administered with a meal and a large glass of water. For daily dosing &ge;800 mg, the 400 mg tablets should be used in order to reduce iron exposure. Do not crush tablets. Tablets may be dispersed in water or apple juice (using ~50 mL for 100 mg tablet, ~200 mL for 400 mg tablet); stir until dissolved and administer immediately. If necessary, an oral suspension may be prepared (see Extemporaneously Prepared). Avoid skin or mucous membrane contact with crushed tablets; if contact occurs, wash thoroughly. Avoid exposure to crushed tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Doses &le;600 mg may be given once daily; 800 mg dose should be administered as 400 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Dosing may be once or twice daily for chronic myeloid leukemia (CML) and once daily for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132628\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181908\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia: </b>Treatment of relapsed or refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of newly diagnosed Ph+ ALL in children (in combination with chemotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aggressive systemic mastocytosis:</b> Treatment of aggressive systemic mastocytosis in adults without D816V c-Kit mutation (as determined by an approved test) or with c-Kit mutational status unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of Ph+ chronic myeloid leukemia (CML) in chronic phase (newly diagnosed) in adults and children</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alfa therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatofibrosarcoma protuberans: </b>Treatment of unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP) in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumors: </b>Treatment of Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjuvant treatment of Kit (CD117)&ndash;positive GIST following complete gross resection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypereosinophilic syndrome and/or chronic eosinophilic leukemia: </b>Treatment of hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) in adult patients who have the FIP1L1&ndash;platelet-derived growth factor (PDGF) receptor alpha fusion kinase (mutational analysis or fluorescent in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGF receptor alpha fusion kinase negative or unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic/Myeloproliferative diseases:</b> Treatment of myelodysplastic syndrome/myeloproliferative diseases (MDS/MPD) associated with PDGF receptor gene rearrangements as determined by an approved test in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474744\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chordoma; Chronic myeloid leukemia (CML) post-stem cell transplantation (SCT) (allogeneic) (follow-up treatment); Desmoid tumor; Melanoma, advanced or metastatic (C-KIT mutated tumors)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401645\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Imatinib may be confused with axitinib, dasatinib, erlotinib, gefitinib, ibrutinib, idelalisib, nilotinib, nintedanib,  PONATinib, SORAfenib, SUNItinib, vandetanib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181898\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions listed as a composite of data across many trials, except where noted for a specific indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (11% to 86%; includes aggravated edema, anasarca, ascites, pericardial effusion, pulmonary edema, and superficial edema), peripheral edema (20% to 41%), facial edema (&le;17%), chest pain (7% to 11%), hypotension (Ph+ ALL; children, adolescents, adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (20% to 75%), pain (&le;47%), headache (8% to 37%), dizziness (5% to 19%), insomnia (9% to 15%), depression (3% to 15%), taste disorder (&le;13%), rigors (10% to 12%), anxiety (8% to 12%), paresthesia (&le;12%), chills (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (9% to 50%), dermatitis (GIST: &le;39%), pruritus (7% to 26%), night sweats (CML: 13% to 17%), alopecia (7% to 15%), diaphoresis (GIST: &le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (&le;60%), weight gain (5% to 32%), decreased serum albumin (&le;21%), hypokalemia (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (41% to 73%), diarrhea (25% to 59%), vomiting (11% to 58%), abdominal pain (3% to 57%), anorexia (&le;36%), dyspepsia (11% to 27%), flatulence (&le;25%), abdominal distension (&le;19%), constipation (8% to 16%), stomatitis (&le;16%), upper abdominal pain (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (3% to 53%; grades 3/4: &le;19%), leukopenia (GIST: 5% to 47%; grades 3/4: 2%), hypoproteinemia (&le;32%), anemia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (&le;38%), increased serum ALT (&le;34%), increased alkaline phosphatase (&le;17%), increased serum bilirubin (&le;13%), increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (Ph+ CML: &le;14%), infection (Ph+ ALL; children, adolescents, adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps (16% to 62%), musculoskeletal pain (adults: 38% to 49%; children: 21%), arthralgia (11% to 40%), myalgia (9% to 32%), weakness (&le;21%), back pain (&le;17%), limb pain (&le;16%), ostealgia (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Periorbital edema (15% to 74%), increased lacrimation (DFSP: 25%; GIST: &le;18%), eyelid edema (Ph+ CML: 19%), blurred vision (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&le;44%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (1% to 31%), cough (11% to 27%), upper respiratory tract infection (3% to 21%), dyspnea (&le;21%), pharyngolaryngeal pain (&le;18%), rhinitis (DFSP: 17%), pharyngitis (CML: 10% to 15%), flu-like symptoms (1% to 14%), pneumonia (CML: 4% to 13%), sinusitis (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 41%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitations (&le;5%), hypertension (&le;4%), cardiac failure (Ph+ CML: 1%), flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Cerebral hemorrhage (&le;9%), hypoesthesia, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin photosensitivity (4% to 7%), xeroderma (&le;7%), erythema, nail disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypophosphatemia (10%), hyperglycemia (&le;10%), weight loss (&le;10%), hypocalcemia (GIST: &le;6%), fluid retention (Ph+ CML: 3%; pleural effusion, pericardial effusion, ascites, or pulmonary edema: 2%), hyperkalemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (10%), gastroenteritis (&le;10%), gastrointestinal hemorrhage (1% to 8%), gastritis, gastroesophageal reflux, increased serum lipase, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (&le;10%; grades 3/4: 1% to 2%), eosinophilia, febrile neutropenia, pancytopenia, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Joint swelling</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (5% to 8%), conjunctival hemorrhage, dry eyes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoxia (9%), oropharyngeal pain (Ph+ CML: &le;6%), epistaxis, pleural effusion, pneumonitis (Ph+ ALL; children, adolescents, adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Actinic keratosis, acute generalized exanthematous pustulosis, anaphylactic shock, angina pectoris, angioedema, aplastic anemia, arthritis, ascites, atrial fibrillation, avascular necrosis of bones, blepharitis, bullous rash, cardiac arrhythmia, cardiac tamponade, cardiogenic shock, cataract, cellulitis, cerebral edema, cheilitis, cold extremities, colitis, confusion, decreased libido, decreased linear skeletal growth rate (children), dehydration, diverticulitis, DRESS syndrome, drowsiness, dyschromia, dysphagia, embolism, eructation, erythema multiforme, esophagitis, exfoliative dermatitis, folliculitis, fungal infection, gastric ulcer, gastrointestinal obstruction, gastrointestinal perforation, glaucoma, gout, gynecomastia, hearing loss, hematemesis, hematoma, hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, herpes simplex infection, herpes zoster, hypercalcemia, hypermenorrhea, hypersensitivity angiitis, hyperuricemia, hypomagnesemia, hyponatremia, hypothyroidism, IgA vasculitis, increased creatine phosphokinase, increased intracranial pressure, inflammatory bowel disease, interstitial pneumonitis, interstitial pulmonary disease, intestinal obstruction, jaundice, left ventricular dysfunction, lichen planus, lower respiratory tract infection, lymphadenopathy, macular edema, melena, memory impairment, menstrual disease, migraine, myocardial infarction, myopathy, onychoclasis, optic neuritis, oral mucosa ulcer, osteonecrosis (hip), ovarian cyst (hemorrhagic), palmar-plantar erythrodysesthesia, pancreatitis, papilledema, pericarditis, petechia, pleuritic chest pain, polyuria, psoriasis, pulmonary fibrosis, pulmonary hemorrhage, pulmonary hypertension, Raynaud phenomenon, reactivation of HBV, renal failure, respiratory failure, restless leg syndrome, retinal hemorrhage, rhabdomyolysis, ruptured corpus luteal cyst, sciatica, scrotal edema, seizure, sepsis, sexual disorder, Stevens-Johnson syndrome, subconjunctival hemorrhage, subdural hematoma, Sweet syndrome, syncope, tachycardia, telangiectasia (gastric antral), thrombocythemia, thrombosis, tinnitus, toxic epidermal necrolysis, tremor, tumor hemorrhage (GIST), tumor lysis syndrome, urinary tract infection, urticaria, vertigo, vesicular eruption, vitreous hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181912\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to imatinib or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181896\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause bone marrow suppression (anemia, neutropenia, and thrombocytopenia), usually occurring within the first several months of treatment. Median duration of neutropenia is 2 to 3 weeks; median duration of thrombocytopenia is 2 to 4 weeks. Monitor blood counts weekly for the first month, biweekly for the second month, and as clinically necessary thereafter. In chronic myeloid leukemia (CML), cytopenias are more common in accelerated or blast phase than in chronic phase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Severe heart failure (HF) and left ventricular dysfunction (LVD) have been reported (occasionally). Cardiac adverse events usually occur in patients with advanced age or comorbidities. Carefully monitor patients with preexisting cardiac disease or risk factors for HF or history of renal failure. With initiation of imatinib treatment, cardiogenic shock and/or LVD have been reported in patients with hypereosinophilic syndrome (HES) and cardiac involvement (reversible with systemic steroids, circulatory support and temporary cessation of imatinib). Echocardiogram and serum troponin monitoring may be considered in patients with HES/chronic eosinophilic leukemia (CEL) and in patients with myelodysplastic/myeloproliferative (MDS/MPD) disease or aggressive systemic mastocytosis associated with high eosinophil levels. Patients with high eosinophil levels and an abnormal echocardiogram or abnormal serum troponin level may benefit from prophylactic systemic steroids (for 1 to 2 weeks) with the initiation of imatinib. In a scientific statement from the American Heart Association, imatinib has been determined to be an agent that may either cause direct myocardial toxicity (rare) or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported; recurrence has been described with rechallenge. Case reports of successful resumption at a lower dose (with corticosteroids and/or antihistamine) have been described; however, some patients may experience recurrent reactions. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. Symptoms of DRESS include fever, severe skin eruption, lymphadenopathy, hematologic abnormalities (eosinophilia or atypical lymphocytes), and internal organ involvement. If symptoms of DRESS occur, interrupt therapy and consider permanently discontinuing; symptoms regressed upon discontinuation of therapy, however, symptoms recurred in all cases when rechallenged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Driving/heavy machinery: Caution is recommended while driving/operating motor vehicles and heavy machinery when taking imatinib; advise patients regarding side effects such as dizziness, blurred vision, or somnolence. Reports of accidents have been received, but it is unclear if imatinib has been the direct cause in any case.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention/edema: Imatinib is commonly associated with fluid retention, weight gain, and edema (risk increases with higher doses and age &gt;65 years); may be occasionally serious and lead to significant complications, including pleural effusion, pericardial effusion, pulmonary edema, and ascites. Monitor regularly for rapid weight gain or other signs/symptoms of fluid retention; rapid unexpected weight gain should be evaluated and managed appropriately. Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Imatinib is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011, Hesketh 2017, Roila 2016). May cause GI irritation; take with food and water to minimize irritation. There have been rare reports (including fatalities) of GI perforation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Severe hemorrhage (grades 3 and 4) has been reported with use, including GI hemorrhage and/or tumor hemorrhage. The incidence of hemorrhage is higher in patients with gastrointestinal stromal tumors (GIST) (GI tumors may have been hemorrhage source). Gastric antral vascular ectasia (a rare cause of gastrointestinal bleeding) has also been reported (Alshehry 2014; Saad Aldin 2012). Monitor for GI symptoms with treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity may occur; fatal hepatic failure and severe hepatic injury requiring liver transplantation have been reported with both short- and long-term use; monitor liver function (transaminases, bilirubin, and alkaline phosphatase) prior to initiation and monthly or as needed thereafter; therapy interruption or dose reduction may be necessary. Transaminase and bilirubin elevations, and acute liver failure have been observed with imatinib in combination with chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Imatinib is associated with a decline in renal function; may be associated with duration of therapy. The median estimated GFR declined from 85 mL/minute/1.73 m<sup>2</sup> at baseline to 75 mL/minute/1.73 m<sup>2</sup> at 12 months and to 69 mL/minute/1.73 m<sup>2</sup> at 60 months (in patients with newly diagnosed chronic myeloid leukemia and malignant GIST). Evaluate renal function prior to imatinib initiation and monitor during therapy. Patients with risk factors for renal dysfunction (eg, preexisting renal impairment, diabetes mellitus, hypertension, congestive heart failure) may be at higher risk for nephrotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been reported in patients with acute lymphoblastic leukemia (ALL), CML eosinophilic leukemias, and GIST. Risk for TLS is higher in patients with a high tumor burden or high proliferation rate; monitor closely. Correct clinically significant dehydration and treat high uric acid levels prior to initiation of imatinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in patients with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric surgery: Imatinib exposure may be reduced in patients who have had gastric surgery (eg, bypass, major gastrectomy, or resection); monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended for moderate and severe renal impairment (CrCl &lt;40 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Hypothyroidism has been reported in thyroidectomy patients who were receiving thyroid hormone replacement therapy prior to initiation of imatinib; monitor thyroid function. The average onset for imatinib-induced hypothyroidism is 2 weeks; consider doubling levothyroxine doses upon initiation of imatinib (Hamnvik 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: The incidence of edema was increased with age older than 65 years in CML and GIST studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Growth retardation has been reported in children receiving imatinib for the treatment of CML; generally where treatment was initiated in prepubertal children; growth velocity was usually restored as pubertal age was reached (Shima 2011). Monitor growth closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Determine PDGFRb gene rearrangements status (for MDS/MPD), D816V c-Kit mutation status (for aggressive systemic mastocytosis [ASM]), Philadelphia chromosome status for acute lymphoblastic leukemia and chronic myeloid leukemia, Kit (CD117)-positivity for GIST, and FIP1L1&ndash;platelet-derived growth factor (PDGF) receptor status for HES or CEL prior to initiating treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181952\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2C9 (weak), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181900\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8961&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May enhance the hepatotoxic effect of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Imatinib may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): Imatinib may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with dexamethasone when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations vary by indication and international labeling. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine: Imatinib may diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP  Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May decrease serum concentrations of the active metabolite(s) of Imatinib. Specifically N-desmethylimatinib concentrations may be decreased. Gemfibrozil may decrease the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.  Management: Extreme caution, with possibly increased monitoring of cardiac status (eg, ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen: May decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lansoprazole: May enhance the dermatologic adverse effect of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May enhance the hepatotoxic effect of Imatinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Imatinib may decrease the metabolism of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of Imatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Telithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Imatinib may enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181926\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may reduce GI irritation. Grapefruit juice may increase imatinib plasma concentration. Management: Take with a meal and a large glass of water. Avoid grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181916\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Imatinib crosses the placenta (Burwick 2017). Spontaneous abortion and congenital anomalies (including skeletal, renal, and GI malformations [Lishner 2016]) have been reported (case reports) following imatinib exposure during pregnancy. Pregnancy should be avoided during imatinib treatment. Pregnancy testing should be conducted in females of reproductive potential prior to therapy; women of reproductive potential should use highly effective contraception during imatinib treatment and for 2 weeks after the last imatinib dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines suggest that imatinib should only be used for the treatment of chronic myeloid leukemia (CML) in the second and third trimester and recommend referral to a facility with expertise in cancer during pregnancy; a multidisciplinary team (obstetrician, neonatologist, oncology team) is encouraged (Peccatori 2013). An international consensus panel suggests delaying treatment until WBC and platelet counts have risen to a level associated with CML symptom onset and then utilizing approaches other than tyrosine kinase inhibitors (Lishner 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3339989\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Imatinib and its active metabolite are present in human breast milk; the milk/plasma ratio is 0.5 for imatinib and 0.9 for the active metabolite. Based on body weight, up to 10% of a therapeutic maternal dose could potentially be received by a breastfed infant. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 month after the last imatinib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181917\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181904\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC (weekly for first month, biweekly for second month, then periodically thereafter), liver function tests (at baseline and monthly or as clinically indicated; more frequently [at least weekly] in patients with moderate-to-severe hepatic impairment [Ramanathan 2008]), renal function (at baseline and periodically thereafter), serum electrolytes (including calcium, phosphorus, potassium and sodium levels); bone marrow cytogenetics (in CML; at 6-, 12-, and 18 months), pregnancy test (prior to treatment in females of reproductive potential); fatigue, weight, and edema/fluid status; consider echocardiogram and serum troponin levels in patients with HES/CEL, and in patients with MDS/MPD or ASM with high eosinophil levels; in pediatric patients, also monitor serum glucose, albumin, and growth</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Gastric surgery (eg, bypass, major gastrectomy, or resection) patients: Monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Thyroid function testing (Hamnvik 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Without preexisting thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2 to 3 months</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor for signs/symptoms of CHF in patients with at risk for cardiac failure or patients with pre-existing cardiac disease. Monitor for signs/symptoms of gastrointestinal irritation or perforation and dermatologic toxicities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181895\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Imatinib inhibits Bcr-Abl tyrosine kinase, the constitutive abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia (CML). Inhibition of this enzyme blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in fresh leukemic cells in Philadelphia chromosome positive CML. Also inhibits tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF), c-Kit, and cellular events mediated by PDGF and SCF.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181911\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Parent drug and metabolite: ~95% to albumin and alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 (minor metabolism via CYP1A2, CYP2D6, CYP2C9, CYP2C19); primary metabolite (active): N-demethylated piperazine derivative (CGP74588); severe hepatic impairment (bilirubin &gt;3 to 10 times ULN) increases AUC  by 45% to 55% for imatinib and its active metabolite, respectively</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:  98%; may be decreased in patients who have had gastric surgery (eg, bypass, total or partial resection) (Liu 2011; Pavlovsky 2009; Yoo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Parent drug: ~18 hours; N-desmethyl metabolite: ~40 hours; Children: Parent drug: ~15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (68% primarily as metabolites, 20% as unchanged drug); urine (13% primarily as metabolites, 5% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181915\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gleevec Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $10,112.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $12,146.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imatinib Mesylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $9,101.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $10,932.11</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181918\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agacel (AR);</li>\n      <li>Alvotinib (UA);</li>\n      <li>Celonib (IN, LK, PE);</li>\n      <li>Egitinid (RO);</li>\n      <li>Enliven (BD);</li>\n      <li>Gemfatinib (RU);</li>\n      <li>Gemivil (JO);</li>\n      <li>Gistamel (RU);</li>\n      <li>Gleevec (BB, ZA);</li>\n      <li>Glibine (AU);</li>\n      <li>Glima (KR);</li>\n      <li>Glimatib (VN);</li>\n      <li>Glinib (KR);</li>\n      <li>Glipox (EE);</li>\n      <li>Glivanib (AU);</li>\n      <li>Glivec (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MX, MY, NL, NO, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Glivic (NZ);</li>\n      <li>Hlivek (UA);</li>\n      <li>Imagerolan (AT);</li>\n      <li>Imagliv (RU);</li>\n      <li>Imakrebin (BG, CZ, HK, NL);</li>\n      <li>Imalek (IN);</li>\n      <li>Imanivec (CZ);</li>\n      <li>Imanix (BD, LK);</li>\n      <li>Imarem (MT, TR);</li>\n      <li>Imatib (AR, IN);</li>\n      <li>Imatin (UY);</li>\n      <li>Imatiqual (AU);</li>\n      <li>Itivas (LV);</li>\n      <li>Kadimer (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kadir (CL);</li>\n      <li>Kimatinib (UY);</li>\n      <li>Leutipol (NL);</li>\n      <li>Leuzek (MT);</li>\n      <li>Matinac (EC);</li>\n      <li>Meaxin (CZ, EE, HR, LV, PL, SK);</li>\n      <li>Mesinib (AR);</li>\n      <li>Mesylonib (IN);</li>\n      <li>Mitinab (IN);</li>\n      <li>Mytib (NZ);</li>\n      <li>Neopax (RU);</li>\n      <li>Neoxell (BG);</li>\n      <li>Nibix (HR, MT, PL);</li>\n      <li>Plivatinib (HR);</li>\n      <li>Protyrin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Survtyk (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tagonib (AR);</li>\n      <li>Tibaldix (NL);</li>\n      <li>Timab (AR, EC, PE);</li>\n      <li>Tinibat (VN);</li>\n      <li>Tinibe (PE);</li>\n      <li>Tivec (AU);</li>\n      <li>Tyrokin (BD);</li>\n      <li>Tyronib (BD);</li>\n      <li>Unitinib (LK);</li>\n      <li>Vek (AR);</li>\n      <li>Zeite (CL, CO, PY);</li>\n      <li>Zeltinib (EC);</li>\n      <li>Ziatir (AR);</li>\n      <li>Zuciel (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alshehry NF, Kortan P, Lipton JH. Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia. <i>Clin Case Rep</i>. 2014;2(3):77-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25356253/pubmed\" target=\"_blank\" id=\"25356253\">25356253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atallah E, Durand JB, Kantarjian H, et al, &ldquo;Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy,&rdquo; <i>Blood</i>, 2007, 110(4):1233-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17449798/pubmed\" target=\"_blank\" id=\"17449798\">17449798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baccarani M, Cortes J, Pane F, et al, &ldquo;Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet,&rdquo; <i>J Clin Oncol</i>, 2009, 27(35):6041-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19884523/pubmed\" target=\"_blank\" id=\"19884523\">19884523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berman E, Nicolaides M, Maki RG, et al, &ldquo;Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate,&rdquo; <i>N Engl J Med</i>, 2006, 354(19):2006-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16687713/pubmed\" target=\"_blank\" id=\"16687713\">16687713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bilgi N, Bell K, Ananthakrishnan AN, et al, &ldquo;Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity,&rdquo; <i>Ann Pharmacother</i>, 2010, 44(5):926-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20332334/pubmed\" target=\"_blank\" id=\"20332334\">20332334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunstein CG and McGlave PB, &ldquo;The Biology and Treatment of Chronic Myelogenous Leukemia,&rdquo; <i>Oncology</i>, 2001, 15:23-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11271979/pubmed\" target=\"_blank\" id=\"11271979\">11271979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burwick RM, Kuo K, Brewer D, Druker BJ. Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. <i>Obstet Gynecol</i>. 2017;129(5):831-834. doi: 10.1097/AOG.0000000000001972.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28383372/pubmed\" target=\"_blank\" id=\"28383372\">28383372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17119111\"></a>Carpenter PA, Snyder DS, Flowers ME, et al, &ldquo;Prophylactic Administration of Imatinib After Hematopoietic Cell Transplantation for High-Risk Philadelphia Chromosome-Positive Leukemia,&rdquo; <i>Blood</i>, 2007, 109(7):2791-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17119111/pubmed\" target=\"_blank\" id=\"17119111\">17119111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21642685\"></a>Carvajal RD, Antonescu CR, Wolchok JD, et al, &ldquo;KIT as a Therapeutic Target in Metastatic Melanoma,&rdquo; <i>JAMA</i>, 2011, 305(22):2327-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21642685/pubmed\" target=\"_blank\" id=\"21642685\">21642685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casali PG, Zalcberg J, Le Cesne A, et al; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. <i>J Clin Oncol</i>. 2017;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28362562/pubmed\" target=\"_blank\" id=\"28362562\">28362562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i>. 2015;125(24):3711-3719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25878120/pubmed\" target=\"_blank\" id=\"25878120\">25878120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20724445\"></a>Chugh R, Wathen JK, Patel SR, et al, &ldquo;Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research Through Collaboration (SARC) Trial,&rdquo; <i>Clin Cancer Res</i>, 2010, 16(19):4884-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20724445/pubmed\" target=\"_blank\" id=\"20724445\">20724445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo; <i>J Support Oncol</i>, 2012, 10(1):14-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22244674/pubmed\" target=\"_blank\" id=\"22244674\">22244674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. <i>J Clin Oncol</i>. 2010;28(3):424-430. doi: 10.1200/JCO.2009.25.3724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20008622/pubmed\" target=\"_blank\" id=\"20008622\">20008622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15297408\"></a>DeAngelo DJ, Hochberg EP, Alyea EP, et al, &ldquo;Extended Follow-Up of Patients Treated With Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse After Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism Without Graft-Versus-Host Disease,&rdquo; <i>Clin Cancer Res</i>, 2004, 10(15):5065-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15297408/pubmed\" target=\"_blank\" id=\"15297408\">15297408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debiec-Rychter M, Sciot R, Le Cesne A, et al, &ldquo;KIT mutations and Dose Selection for Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors,&rdquo; <i>Eur J Cancer</i>, 2006, 42(8):1093-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16624552/pubmed\" target=\"_blank\" id=\"16624552\">16624552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Groot JW, Zonnenberg BA, Plukker JT, et al, &quot;Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine,&quot; <i>Clin Pharmacol Ther</i>, 2005, 78(4):433-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16198662/pubmed\" target=\"_blank\" id=\"16198662\">16198662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dematteo RP, Ballman KV, Antonescu CR, et al, &ldquo;Adjuvant Imatinib Mesylate After Resection of Localised, Primary Gastrointestinal Stromal Tumour: a Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>Lancet</i>, 2009, 373(9669):1097-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19303137/pubmed\" target=\"_blank\" id=\"19303137\">19303137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dewar AL, Farrugia AN, Condina MR, et al, &ldquo;Imatinib as a Potential Antiresorptive Therapy for Bone Disease,&rdquo; <i>Blood</i>, 2006, 107(11):4334-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16449525/pubmed\" target=\"_blank\" id=\"16449525\">16449525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al, &ldquo;Imatinib Mesylate in the Treatment of Systemic Mastocytosis: A Phase II Trial,&rdquo; <i>Cancer</i>, 2006, 107(2):345-51<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16779792/pubmed\" target=\"_blank\" id=\"16779792\">16779792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Druker BJ, Sawyers CL, Kantarjian H, et al, &ldquo;Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia With the Philadelphia Chromosome,&rdquo; <i>N Engl J Med</i>, 2001, 344(14):1038-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287973/pubmed\" target=\"_blank\" id=\"11287973\">11287973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Druker BJ, Talpaz M, Resta DJ, et al, &ldquo;Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia,&rdquo; <i>N Engl J Med</i>, 2001, 344(14):1031-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287972/pubmed\" target=\"_blank\" id=\"11287972\">11287972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eechoute K, Fransson MN, Reyners AK, et al, &ldquo;A Long-Term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients,&rdquo; <i>Clin Cancer Res</i>, 2012, 18(20):5780-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22850565/pubmed\" target=\"_blank\" id=\"22850565\">22850565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. <i>J Clin Oncol</i>. 2017;35(3):298-305. doi: 10.1200/JCO.2016.68.2914.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28095277/pubmed\" target=\"_blank\" id=\"28095277\">28095277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farag S, Somaiah N, Chooi H, et al. Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients (abstract). J Clin Oncol 34, 2016 (suppl; abstr 11011). Abstract available online at http://meetinglibrary.asco.org/content/164473-176 (Accessed on Sept 13, 2016).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gambacorti-Passerini C, Antolini L, Mahon FX, et al, &ldquo;Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(7):553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21422402/pubmed\" target=\"_blank\" id=\"21422402\">21422402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons J, Egorin MJ, Ramanathan RK, et al, &ldquo;Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group,&rdquo; <i>J Clin Oncol</i>, 2008, 26(4):570-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18235116/pubmed\" target=\"_blank\" id=\"18235116\">18235116</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; received September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gleevec (imatinib) [product monograph]. Dorval, Quebec Canada: Novartis Pharmaceuticals Canada Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gotlib J, Cools J, Malone JM 3rd, et al, &ldquo;The FIP1L1-PDGFRalpha Fusion Tyrosine Kinase in Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia: Implications for Diagnosis, Classification, and Management,&rdquo; <i>Blood</i>, 2004, 103(8):2879-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15070659/pubmed\" target=\"_blank\" id=\"15070659\">15070659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hehlmann R, Hochhaus A, Berger U, et al, &ldquo;Current Trends in the Management of Chronic Myelogenous Leukemia,&rdquo; <i>Ann Hematol</i>, 2000, 79:345-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/10965782/pubmed\" target=\"_blank\" id=\"10965782\">10965782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hehlmann R, M&uuml;ller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. <i>J Clin Oncol</i>. 2014;32(5):415-423. doi: 10.1200/JCO.2013.49.9020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/24297946/pubmed\" target=\"_blank\" id=\"24297946\">24297946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinrich MC, Owzar K, Corless CL, et al, &ldquo;Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group,&rdquo; <i>J Clin Oncol</i>, 2008, 26(33):5360-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18955451/pubmed\" target=\"_blank\" id=\"18955451\">18955451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guidelines update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16234522\"></a>Hess G, Bunjes D, Siegert W, et al, &ldquo;Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7583-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16234522/pubmed\" target=\"_blank\" id=\"16234522\">16234522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. <i>N Engl J Med</i>. 2017;376(10):917-927. doi: 10.1056/NEJMoa1609324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28273028/pubmed\" target=\"_blank\" id=\"28273028\">28273028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochhaus A, O'Brien SG, Guilhot F, et al, &ldquo;Six-Year Follow-Up of Patients Receiving Imatinib for the First-Line Treatment of Chronic Myeloid Leukemia,&rdquo; <i>Leukemia</i>, 2009, 23(6):1054-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19282833/pubmed\" target=\"_blank\" id=\"19282833\">19282833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ibrahim AR, Eliasson L, Apperley JF, et al, &ldquo;Poor Adherence is the Main Reason for Loss of CCyR and Imatinib Failure for Chronic Myeloid Leukemia Patients on Long-Term Therapy,&rdquo; <i> Blood</i>, 2011, 117(14):3733-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21346253/pubmed\" target=\"_blank\" id=\"21346253\">21346253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joensuu H, Eriksson M, Sundby Hall K, et al, &ldquo;One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial,&rdquo; <i>JAMA</i>, 2012, 307(12):1265-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22453568/pubmed\" target=\"_blank\" id=\"22453568\">22453568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al, &ldquo;Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient With a Metastatic Gastrointestinal Stromal Tumor,&rdquo; <i>N Engl J Med</i>, 2001, 344(14):1052-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287975/pubmed\" target=\"_blank\" id=\"11287975\">11287975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, O'Brien S, Cortes JE, et al, &ldquo;Imatinib Mesylate Therapy for Relapse After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia,&rdquo; <i>Blood</i>, 2002, 100(5):1590-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/12176876/pubmed\" target=\"_blank\" id=\"12176876\">12176876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Sawyers C, Hochhaus A, et al, &ldquo;Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia,&rdquo; <i>N Engl J Med</i>, 2002, 346:645-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11870241/pubmed\" target=\"_blank\" id=\"11870241\">11870241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerkela R, Grazette L, Yacobi R, et al, &ldquo;Cardiotoxicity of the Cancer Therapeutic Agent Imatinib Mesylate,&rdquo; <i>Nat Med</i>, 2006, 12(8):908-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16862153/pubmed\" target=\"_blank\" id=\"16862153\">16862153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Druker BJ, Guilhot F, et al, &ldquo;Imatinib Pharmacokinetics and its Correlation With Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study,&rdquo; <i>Blood</i>, 2008, 111(8):4022-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18256322/pubmed\" target=\"_blank\" id=\"18256322\">18256322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Cesne A, Ray-Coquard I, Bui BN, et al, &ldquo;Discontinuation of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumours After 3 Years of Treatment: An Open-Label Multicentre Randomised Phase 3 Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(10):942-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20864406/pubmed\" target=\"_blank\" id=\"20864406\">20864406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Cesne A, Van Glabbeke M, Verweij J, et al, &ldquo;Absence of Progression as Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial,&rdquo; <i>J Clin Oncol</i>, 2009, 27(24):3969-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19620483/pubmed\" target=\"_blank\" id=\"19620483\">19620483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Q, Liu Z, Kolli S, et al. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspension. <i>Am J Health Syst Pharm.</i> 2016;73(17):1331-1337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27543577/pubmed\" target=\"_blank\" id=\"27543577\">27543577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi: 10.1200/JCO.2015.62.4445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/26628463/pubmed\" target=\"_blank\" id=\"26628463\">26628463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu H and Artz AS, &ldquo;Reduction of Imatinib Absorption After Gastric Bypass Surgery,&rdquo; <i>Leuk Lymphoma</i>, 2011, 52(2):310-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21133728/pubmed\" target=\"_blank\" id=\"21133728\">21133728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahon FX, R&eacute;a D, Guilhot J, et al, &ldquo;Discontinuation of Imatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: the Prospective, Multicentre Stop Imatinib (STIM) Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(11):1029-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20965785/pubmed\" target=\"_blank\" id=\"20965785\">20965785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. <i>Ann Oncol</i>. 2011;22(9):2073-2079.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21310760/pubmed\" target=\"_blank\" id=\"21310760\">21310760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McArthur GA, Demetri GD, van Oosterom A, et al, &ldquo;Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated with Imatinib: Imatinib Target Exploration Consortium Study B2225,&rdquo; <i>J Clin Oncol</i>, 2005, 23(4):866-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15681532/pubmed\" target=\"_blank\" id=\"15681532\">15681532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17881635\"></a>Olavarria E, Siddique S, Griffiths MJ, et al, &ldquo;Posttransplantation Imatinib as a Strategy to Postpone the Requirement for Immunotherapy in Patients Undergoing Reduced-Intensity Allografts for Chronic Myeloid Leukemia,&rdquo; <i>Blood</i>, 2007, 110(13):4614-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17881635/pubmed\" target=\"_blank\" id=\"17881635\">17881635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottmann OG, Wassmann B, Pfeifer H, et al, &ldquo;Imatinib Compared With Chemotherapy as Front-Line Treatment of Elderly Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL),&rdquo; <i>Cancer</i>, 2007, 109(10):2068-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17429836/pubmed\" target=\"_blank\" id=\"17429836\">17429836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pavlovsky C, Egorin MJ, Shah DD, et al, &ldquo;Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient With Chronic Myeloid Leukemia,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(9):1152-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19698017/pubmed\" target=\"_blank\" id=\"19698017\">19698017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/23813932/pubmed\" target=\"_blank\" id=\"23813932\">23813932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20622000\"></a>Penel N, Le Cesne A, Bui BN, et al, &ldquo;Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC/French Sarcoma Group Phase II trial With a Long-Term Follow-up,&rdquo; <i>Ann Oncol</i>, 2011, 22(2):452-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20622000/pubmed\" target=\"_blank\" id=\"20622000\">20622000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramanathan RK, Egorin MJ, Takimoto CH, et al, &ldquo;Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group,&rdquo; <i>J Clin Oncol</i>, 2008, 26(4):563-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18235115/pubmed\" target=\"_blank\" id=\"18235115\">18235115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saad Aldin E, Mourad F, Tfayli A. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review. <i>Jpn J Clin Oncol</i>. 2012;42(5):447-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22422898/pubmed\" target=\"_blank\" id=\"22422898\">22422898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. <i>J Clin Oncol</i>. 2009;27(31):5175-5181. doi: 10.1200/JCO.2008.21.2514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19805687/pubmed\" target=\"_blank\" id=\"19805687\">19805687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shima H, Tokuyama M, Tanizawa A, et al, &ldquo;Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children With Chronic Myeloid Leukemia,&rdquo; <i>J Pediatr</i>, 2011, 159(4):676-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21592517/pubmed\" target=\"_blank\" id=\"21592517\">21592517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22331945\"></a>Stacchiotti S, Longhi A, Ferraresi V, et al, &ldquo;Phase II Study of Imatinib in Advanced Chordoma,&rdquo; <i>J Clin Oncol</i>, 2012, 30(9):914-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22331945/pubmed\" target=\"_blank\" id=\"22331945\">22331945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stacchiotti S, Marrari A, Tamborini E, et al, &ldquo;Response to Imatinib Plus Sirolimus in Advanced Chordoma,&rdquo; <i>Ann Oncol</i>, 2009, 20(11):1886-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19570961/pubmed\" target=\"_blank\" id=\"19570961\">19570961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, Faderl S, Cortes J, et al, &ldquo;Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia With Hyper-CVAD and Imatinib Mesylate,&rdquo; <i>Blood</i>, 2004, 103(12):4396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/14551133/pubmed\" target=\"_blank\" id=\"14551133\">14551133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Mehren M and Widmer N, &ldquo;Correlations Between Imatinib Pharmacokinetics, Pharmacodynamics, Adherence, and Clinical Response in Advanced Metastatic Gastrointestinal Stromal Tumor (GIST): An Emerging Role for Drug Blood Level Testing?&rdquo; <i>Cancer Treat Rev</i>, 2011, 37(4):291-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21078547/pubmed\" target=\"_blank\" id=\"21078547\">21078547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanada M, Takeuchi J, Sugiura I, et al, &ldquo;High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group,&rdquo; <i>J Clin Oncol</i>, 2006, 24(3):460-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16344315/pubmed\" target=\"_blank\" id=\"16344315\">16344315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i>. 2015;125(6):915-923.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25519749/pubmed\" target=\"_blank\" id=\"25519749\">25519749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoo C, Ryu MH, Kang BW, et al, &ldquo;Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib,&rdquo; <i>J Clin Oncol</i>, 2010, 28(9):1554-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20177019/pubmed\" target=\"_blank\" id=\"20177019\">20177019</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8961 Version 223.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181929\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181930\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181958\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181934\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F181948\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181935\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6797530\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F181936\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F181959\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181906\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181892\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181909\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132628\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181908\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474744\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401645\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181898\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181912\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181896\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F181952\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181900\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F181926\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181916\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3339989\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F181917\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181904\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181895\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181911\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181915\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181918\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8961|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=imatinib-patient-drug-information\" class=\"drug drug_patient\">Imatinib: Patient drug information</a></li><li><a href=\"topic.htm?path=imatinib-pediatric-drug-information\" class=\"drug drug_pediatric\">Imatinib: Pediatric drug information</a></li></ul></div></div>","javascript":null}